Iterum Therapeutics plc (ITRMF) Interest & Investment Income (2017 - 2025)

Iterum Therapeutics has reported Interest & Investment Income for 9 years, with the latest figure at -$441000.0 in Q3 2025.

• On a quarterly basis, Interest & Investment Income rose 25.25% year-over-year to -$441000.0 in Q3 2025; TTM through Sep 2025 was -$2.2 million, a 297.36% decrease from a year earlier, with the FY2024 full-year figure at -$2.5 million, down 246.46% from the prior year.
• Interest & Investment Income was -$441000.0 for Q3 2025 at Iterum Therapeutics, down from -$316000.0 in the prior quarter.
• The five-year high for Interest & Investment Income was $2.7 million in Q4 2023, with the low at -$3.0 million in Q1 2021.
• Average Interest & Investment Income over 5 years is -$526578.9, with a median of -$571000.0 recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Interest & Investment Income jumped 3331.25% in 2023, then tumbled 131.84% in 2024.
• Over 5 years, Interest & Investment Income stood at -$772000.0 in 2021, then soared by 110.36% to $80000.0 in 2022, then surged by 3331.25% to $2.7 million in 2023, then sank by 131.84% to -$874000.0 in 2024, then jumped by 49.54% to -$441000.0 in 2025.
• The last three Interest & Investment Income figures came in at -$441000.0 (Q3 2025), -$316000.0 (Q2 2025), and -$534000.0 (Q1 2025), per Business Quant data.